Form 13-F position report

GLOBUS MED INC

Reported by Vestal Point Capital LP

GMED CUSIP 379577208 Manager CIK 0001974915

Reported 915,000 shares, up 65,000 (7.6%) from the prior quarter.

Reported value 2.0%; share count 7.6% vs. the prior quarter.

Added
% of reported 13F value 1.77% This manager · Q3 2026
Shares 915,000 Quarter-end amount reported
Reported value $68,533,500 Fair value at quarter end
Consecutive quarters held 12 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-12-31 42632000
2024-03-31 53640000
2024-06-30 61641000
2024-09-30 0
2024-12-31 26880750
2025-03-31 14640000
2025-06-30 29510000
2025-09-30 71587500
2025-12-31 111320250
2026-03-31 52602403
2026-06-30 67158500
2026-09-30 68533500

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for GLOBUS MED INC held by Vestal Point Capital LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 915,000 +65,000 (7.6%) 1.77% $68,533,500 2026-11-16
Q2 2026 Added 850,000 +239,480 (39.2%) 1.57% $67,158,500 2026-08-14
Q1 2026 Reduced 610,520 -664,480 (-52.1%) 1.47% $52,602,403 2026-05-15
Q4 2025 Added 1,275,000 +25,000 (2.0%) 3.78% $111,320,250 2026-02-17
Q3 2025 Added 1,250,000 +750,000 (150.0%) 3.23% $71,587,500 2025-11-14
Q2 2025 Added 500,000 +300,000 (150.0%) 1.55% $29,510,000 2025-08-14
Q1 2025 Reduced 200,000 -125,000 (-38.5%) 1.05% $14,640,000 2025-05-15
Q4 2024 New 325,000 +325,000 (0.0%) 1.59% $26,880,750 2025-02-14
Q3 2024 Reduced 0 -900,000 (-100.0%) 0 $0 2024-11-14
Q2 2024 Reduced 900,000 -100,000 (-10.0%) 4.6% $61,641,000 2024-08-14
Q1 2024 Added 1,000,000 +200,000 (25.0%) 4.44% $53,640,000 2024-05-14
Q4 2023 New 800,000 +800,000 (0.0%) 4.52% $42,632,000 2024-02-13

Who else reported the position

684 managers reported GLOBUS MED INC for Q3 2026.

Managers reporting GLOBUS MED INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 10,906,047 +99,323 0.01% $816,862,956 9 qtrs
JANUS HENDERSON GROUP PLC Added 8,634,195 +1,011,100 0.27% $646,722,089 1 qtr
VANGUARD CAPITAL MANAGEMENT LLC Reduced 5,075,559 -31,973 < 0.01% $380,159,369 3 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 4,866,366 -128,019 0.02% $364,490,813 3 qtrs
STATE STREET CORPORATION Added 3,718,553 +4,524 < 0.01% $278,519,620 54 qtrs
Boston Partners Added 3,415,554 +1,860,564 0.23% $255,897,564 2 qtrs
JPMorgan Chase & Co Added 3,158,516 +414,666 0.01% $239,549,935 49 qtrs
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Reduced 3,196,729 -1,083,001 0.9% $239,435,002 2 qtrs
DIMENSIONAL FUND ADVISORS LP Added 3,007,442 +638,132 0.04% $225,264,959 52 qtrs
Swedbank AB Added 2,880,843 +2,360,480 0.18% $215,775,142 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
CL A

Voting authority reported

Sole
915,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.